Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

r cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including metastatic melanoma, lung cancer, breast cancer and as an adjuvant therapy for kidney cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events >/=20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division o
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
4. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 Research ... the "Animal Genetics Market by Products, by Testing ... their offering. The global animal genetics market ... 2014 and grow at a CAGR of 8-9% during ... This market is mainly driven by increasing animal protein ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... cooperative research center program (I/UCRC) will "provide a one-stop ... wide range of metamaterials." Dr. David Crouse, associate ... Engineering at The City College of New York, serves ... Participating institutions are The City University of ...
... Inc. (OTCBB: PEDX) announced that the U.S. Centers ... state Medicaid agencies to include PediatRx,s GRANISOL, NDC ... funds the Medicaid and State Children Health Insurance ... health insurance, including prescription drug coverage, to over ...
... 2011 Cellular Dynamics International (CDI), the ... induced pluripotent stem cell (iPSC) lines, today announced it ... patented definitive endoderm differentiation technology from ViaCyte, Inc. ... CDI will apply this patented methodology in the development ...
Cached Biology Technology:Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 2GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 3GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 4Cellular Dynamics Licenses Technology From ViaCyte 2Cellular Dynamics Licenses Technology From ViaCyte 3
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... in the Proceedings of the National Academy of Sciences ... from the Kennedy Krieger Institute and four collaborating institutions, identified ... to the development of glaucoma and its resulting vision loss. ... head, the point where the cables that carry information from ...
... researchers led by Daniel J. Rader, MD, associate ... and Therapeutics, has received a $6 million grant ... molecular genetics of atherosclerotic cardiovascular disease. The team,s ... Plasma Lipids and Cardiovascular Disease," was selected to ...
... vomiting hairballs or refusing to eat probably isn,t being finicky ... is a good chance that the cat is acting sick ... new research suggests. Healthy cats were just as likely ... leave waste outside their litter box in response to changes ...
Cached Biology News:New research reveals unexpected biological pathway in glaucoma 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Even healthy cats act sick when their routine is disrupted 2Even healthy cats act sick when their routine is disrupted 3Even healthy cats act sick when their routine is disrupted 4Even healthy cats act sick when their routine is disrupted 5
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... top-of-the-line PowerPac 3000 power supply is ... ideal for isoelectric focusing, DNA sequencing, ... electrophoresis, western blotting, and submerged gel ... of powre, the PowerPac 3000 power ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The wide mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
Biology Products: